Dark

Check out our API

CYCCP
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock
stock NASDAQ

Inactive

Sep 11, 2025

5.05USD-4.356%(-0.23)6,463

Pre-market

0.00USD-100.000%(-5.28)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

07:00AM EST Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib GlobeNewswire Inc

Dec 23, 2021

07:00AM EST Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 GlobeNewswire Inc

Nov 5, 2021

09:46AM EDT Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Fadraciclib In Patients With Leukemias Or Myelodysplastic Syndromes Benzinga

09:42AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Companys multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS). GlobeNewswire Inc

Oct 29, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial GlobeNewswire Inc

Sep 8, 2021

07:00AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September. GlobeNewswire Inc

Aug 11, 2021

04:05PM EDT - Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -- Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow -- Cash Runway to Early 2023 -- Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET - GlobeNewswire Inc

Aug 3, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial GlobeNewswire Inc

Jul 13, 2021

07:05AM EDT Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas Benzinga

07:01AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Companys multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors. GlobeNewswire Inc

Jul 7, 2021

07:15AM EDT Cyclacel Pharmaceuticals to Present at Ladenburg GlobeNewswire Inc

May 12, 2021

04:05PM EDT - Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -- Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -- Following Recent Financing, Cash Runway Extended to Early 2023 -- Conference Call Scheduled May 12, 2021 at 4:30 p.m. ET - GlobeNewswire Inc

May 5, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial GlobeNewswire Inc

Mar 16, 2021

04:05PM EDT Cyclacel Pharmaceuticals Announces Closing of $14.5 Million GlobeNewswire Inc

Mar 15, 2021

07:18AM EDT Cyclacel To Present At Oppenheimer 31st Annual Healthcare Conference Mar. 18 At 9:20 a.m. ET Benzinga

07:16AM EDT Cyclacel to Present at the Oppenheimer 31st Annual Healthcare GlobeNewswire Inc

Mar 12, 2021

08:33AM EST Cyclacel Pharmaceuticals Prices 1,807,143 Share Common Stock Offering At $7/Share Benzinga

08:30AM EST Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public GlobeNewswire Inc

Mar 11, 2021

04:01PM EST Cyclacel Pharmaceuticals Announces Proposed Public Offering of GlobeNewswire Inc

Feb 19, 2021

07:00AM EST Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year GlobeNewswire Inc

Feb 10, 2021

07:00AM EST Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & GlobeNewswire Inc

Jan 11, 2021

07:53AM EST Cyclacel Pharmaceuticals Announces Key Business Objectives For 2021 Benzinga

07:46AM EST Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures GlobeNewswire Inc

Dec 30, 2020

07:00AM EST Cyclacel Pharmaceuticals to Present at Biotech GlobeNewswire Inc

Dec 22, 2020

08:00AM EST - Strategic investment from single biotech-focused institutional investor - GlobeNewswire Inc

Dec 21, 2020

07:00AM EST Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election ofBrian Schwartz, M.D., to its Board of Directors. GlobeNewswire Inc

Nov 11, 2020

04:05PM EST Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2020 and certain business highlights. GlobeNewswire Inc

Oct 26, 2020

08:28AM EDT Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity, Good Oral Bioavailability Of Fadraciclib In Patients With Advanced Solid Tumors At EORTC-NCI-AACR Symposium 2020 Benzinga

08:26AM EDT Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor GlobeNewswire Inc

Oct 23, 2020

04:30PM EDT Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, GlobeNewswire Inc

Oct 5, 2020

07:00AM EDT Cyclacel Pharmaceuticals to Present at the October 2020 Lytham GlobeNewswire Inc

Sep 21, 2020

07:08AM EDT Cyclacel Announces Fadraciclib Abstract Selected For Oral Presentation In The Late Breaking And Best Proffered Paper Session At 32nd EORTC-NCI-AACR Symposium 2020 Sat. Oct. 24 Benzinga

07:00AM EDT Cyclacel Announces Fadraciclib Abstract Selected for Oral GlobeNewswire Inc

Aug 12, 2020

04:06PM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK2/9 inhibitor. GlobeNewswire Inc

Aug 5, 2020

07:01AM EDT Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial GlobeNewswire Inc

Jul 13, 2020

07:06AM EDT Cyclacel's Highlights Publication Of Peer-Reviewed Study Of Clinical Stage CDK2/9 Inhibitor Fadraciclib Benzinga

07:00AM EDT -- Characterization of fadraciclib published in peer-reviewed journal shows specificity against GlobeNewswire Inc

Share